BGLC
Income statement / Annual
Last year (2024), BioNexus Gene Lab Corp.'s total revenue was $9.51 M,
a decrease of 2.66% from the previous year.
In 2024, BioNexus Gene Lab Corp.'s net income was -$1.60 M.
See BioNexus Gene Lab Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$9.51 M |
$9.77 M |
$10.93 M |
$13.36 M |
$11.39 M |
$126.96 K |
$212.33 K |
$107.68 K |
$0.00 |
| Cost of Revenue |
$8.22 M
|
$8.44 M
|
$9.67 M
|
$11.17 M
|
$9.67 M
|
$71.07 K
|
$183.56 K
|
$28.87 K
|
$0.00
|
| Gross Profit |
$1.29 M
|
$1.33 M
|
$1.26 M
|
$2.19 M
|
$1.72 M
|
$55.89 K
|
$28.77 K
|
$78.81 K
|
$0.00
|
| Gross Profit Ratio |
0.14
|
0.14
|
0.12
|
0.16
|
0.15
|
0.44
|
0.14
|
0.73
|
0
|
| Research and Development Expenses |
$47.51 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$1.97 M
|
$2.44 M
|
$1.73 M
|
$1.20 M
|
$1.33 M
|
$356.64 K
|
$241.93 K
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$2.03 M
|
$596.86 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.00 M
|
$3.04 M
|
$1.73 M
|
$1.20 M
|
$1.33 M
|
$356.64 K
|
$241.93 K
|
$206.72 K
|
$835.00
|
| Other Expenses |
$0.00
|
$379.19 K
|
-$179.28 K
|
-$66.49 K
|
-$886.94 K
|
-$25.05 K
|
$273.07 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$2.86 M
|
$3.92 M
|
$1.55 M
|
$1.14 M
|
$446.00 K
|
$331.59 K
|
-$31.14 K
|
$206.72 K
|
$835.00
|
| Cost And Expenses |
$8.21 M
|
$12.36 M
|
$11.22 M
|
$12.31 M
|
$10.12 M
|
$402.66 K
|
$152.43 K
|
$235.59 K
|
$835.00
|
| Interest Income |
$147.64 K
|
$0.00
|
$12.48 K
|
$12.97 K
|
$11.31 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$21.15 K
|
$13.93 K
|
$12.48 K
|
$12.97 K
|
$11.31 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$153.14 K
|
$108.42 K
|
$105.42 K
|
$108.22 K
|
$101.60 K
|
$53.33 K
|
$40.61 K
|
$15.03 K
|
$835.00
|
| EBITDA |
-$1.42 M |
-$2.49 M |
-$185.76 K |
$1.16 M |
$1.38 M |
-$222.37 K |
$100.51 K |
-$104.38 K |
$0.00 |
| EBITDA Ratio |
-0.15
|
-0.25
|
-0.02
|
0.09
|
0.12
|
-1.75
|
0.47
|
-0.97
|
0
|
| Operating Income Ratio |
-0.17
|
-0.27
|
-0.03
|
0.08
|
0.11
|
-2.17
|
0.28
|
-1.19
|
0
|
| Total Other Income/Expenses Net |
-$21.15 K
|
-$13.93 K
|
-$12.48 K
|
-$12.97 K
|
-$11.31 K
|
$0.00
|
$0.00
|
$0.00
|
$5.00
|
| Income Before Tax |
-$1.59 M
|
-$2.61 M
|
-$303.66 K
|
$1.04 M
|
$1.26 M
|
-$275.71 K
|
$59.90 K
|
-$119.41 K
|
-$835.00
|
| Income Before Tax Ratio |
-0.17
|
-0.27
|
-0.03
|
0.08
|
0.11
|
-2.17
|
0.28
|
-1.11
|
0
|
| Income Tax Expense |
$3.49 K
|
$21.53 K
|
$52.31 K
|
$291.28 K
|
$168.41 K
|
-$29.24 K
|
$33.45 K
|
$4.34 K
|
-$835.00
|
| Net Income |
-$1.60 M
|
-$2.63 M
|
-$355.97 K
|
$751.57 K
|
$1.09 M
|
-$246.47 K
|
$26.45 K
|
-$123.75 K
|
-$835.00
|
| Net Income Ratio |
-0.17
|
-0.27
|
-0.03
|
0.06
|
0.1
|
-1.94
|
0.12
|
-1.15
|
0
|
| EPS |
-0.09 |
-0.17 |
-0.0247 |
0.0527 |
0.13 |
-0.0342 |
0.0048 |
-0.0199 |
-0.0001 |
| EPS Diluted |
-0.09 |
-0.17 |
-0.0247 |
0.0527 |
0.13 |
-0.0342 |
0.0048 |
-0.0199 |
-0.0001 |
| Weighted Average Shares Out |
$1.78 M
|
$158.76 K
|
$1.44 M
|
$1.43 M
|
$857.65 K
|
$719.74 K
|
$552.80 K
|
$621.90 K
|
$621.90 K
|
| Weighted Average Shares Out Diluted |
$1.78 M
|
$158.76 K
|
$1.44 M
|
$1.43 M
|
$857.65 K
|
$719.74 K
|
$552.80 K
|
$621.90 K
|
$621.90 K
|
| Link |
|
|
|
|
|
|
|
|
|
